News | May 23, 2025
Biocon gets six-month extension on insulin supply pact in Malaysia
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)
This marks yet another milestone in our series of successful audits over the past year
The change of name has been carried on pursuant to the Scheme of Amalgamation
This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
These observations are procedural in nature and none of them are related to data integrity
The FDA issued Form 483 with one observation related to building and facility management
Subscribe To Our Newsletter & Stay Updated
